

# **UBS Investment Research PG&E Corporation**

## **CPUC End Game Begins**

### Senate fails to act on confirming Commissioner Ryan

We confirmed with the CPUC that Commissioner Ryan was not confirmed by the California Senate by the statutory deadline of January 20, 2011. This now leaves the five person CPUC in a two member, non-quorum position.

### **■** Governor Brown now has three appointments to make

Gov. Brown will now have three nominees to the CPUC, none of whom are known at this time. Our working assumption is that Gov Brown will want to have his nominees with him during the 100 year anniversary celebration of the CPUC, which is on January 27. We hope the new CPUC will continue to equitably balance consumer and shareholder interests; we believe Chairman Peevey has done just that and has been a stabilizing balance on the commission.

## ■ Settlement decision delayed; cost of capital formula coming into focus

At a minimum, we believe there will be a further delay in rendering a decision in PCG's pending GRC settlement. In addition to the quorum issue, our view is the CPUC will need at least an additional month to "get up to speed" on this proceeding. Separately, the makeup of the CPUC commissioners could influence the cost of capital formula which was sanctioned and administered by the CPUC and is due for re-examination in mid-2012.

#### ■ Valuation – Fairly valued at current levels; Maintain Neutral rating

Our \$49 target price remains intact, and is derived using a combination of P/E, DDM, and DCF valuation methodologies.

Highlights (US\$m)	12/08	12/09	12/10E	12/11E	12/12E
Revenues	14,628	13,399	13.900	14.495	15.013
EBIT (UBS)	2,337	2,385	2,742	3,091	3,308
Net Income (UBS)	1,081	1,220	1,347	1,496	1,580
EPS (UBS, US\$)	2.95	3.16	3.45	3.71	3.87
Net DPS (UBS, US\$)	1.56	1.65	1.79	1.93	2.04
Profitability & Valuation	5-yr hist av.	12/09	12/10E	12/11E	12/12E
Profitability & Valuation EBIT margin %	5-yr hist av. 26.6	<b>12/09</b> 17.8	<b>12/10E</b> 19.7	<b>12/11E</b> 21.3	<b>12/12E</b> 22.0
EBIT margin %	26.6	17.8	19.7	21.3	22.0
EBIT margin % ROIC (EBIT) %	26.6	17.8 7.1	19.7 7.5	21.3 8.0	22.0 8.1
EBIT margin % ROIC (EBIT) % EV/EBITDA (core) x	26.6 12.1	17.8 7.1 9.3	19.7 7.5 9.3	21.3 8.0 8.4	22.0 8.1 7.8

Valuations: based on an average share price that year, (E): based on a share price of US\$47.00 on 20 Jan 2011 19:40 EST

Jim von Riesemann	Julien Dumoulin-Smith	David Eads
Analyst	Analyst	Associate Analyst
jim.vonriesemann@ubs.com	julien.dumoulin-smith@ubs.com	david.eads@ubs.com
+1-212-713-4260	+1 212 -713 9848	+1 212 713 3630

Global Equity Res	earch
Americas	
Electric Utilities	
12-month rating	Neutral Unchanged
12m price target	US\$49.00 <i>Unchanged</i>
Price	US\$47.00
RIC: PCG.N BBG: PCG US	
	21 January 2011
Tradingdata	
52-wk range	US\$48.58-40.00
Vlarket cap.	US\$17.4bn
Shares o/s	371m (COM)
Free float	100%

Balance sheet data 12/10E	
Shareholders' equity	US\$11.2bn
P/BV (UBS)	1.6x
Net Cash (debt)	(US\$13.8bn)
Forecast returns	
Forecast price appreciation	+4.3%
Forecast dividend yield	4.1%
Forecast stock return	+8.4%

741

US\$35.2

5.6% Market return assumption Forecast excess return +2.8%

EPS (UBS, US\$)

Avg. daily volume ('000)

Avg. daily value (m)

	12	/10E	12/09
	UBS	Cons.	Actual
Q1	0.79	0.79	0.66
Q2	0.91	0.91	0.83
Q3	1.02	1.02	0.93
Q4E	0.73	0.72	0.79
12/10E	3.45	3.43	
12/11E	3.71	3.71	
		·	



www.ubs.com/investmentresearch

UBS does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

## **■ PG&E Corporation**

PG&E Corporation operates principally through its regulated utility, Pacific Gas & Electric, which provides both electric and gas transmission and distribution services, in addition to electric generation. The T&D business serves 5.1 million electric and 4.3 million gas customers in central and northern California, covering an area of approximately 70,000 square miles. The company also operates a generation fleet of 6,300 MW, consisting mostly of hydroelectric and nuclear power.

#### **■** Statement of Risk

Investors should aware of the following risks to PCG shares: Unreasonable or unexpected regulatory/legal decisions; the potential impact of rising energy use to exceed mitigation targets; adverse CPUC decisions, particularly in its Cost of Capital and (General Rate Case) GRC filings; adverse FERC decisions regardings its federally regulated transmission assets; failure to implement adequate and unexpected changes to the financial health of the company that could result in debt downgrades and collateral calls from counter parties.

## ■ Analyst Certification

Each research analyst primarily responsible for the content of this research report, in whole or in part, certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report.

## Required Disclosures

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.

For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical performance information; and certain additional disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures. The figures contained in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy businesses by the China Securities Regulatory Commission.

## UBS Investment Research: Global Equity Rating Allocations

UBS 12-Month Rating	Rating Category	Coverage <sup>1</sup>	IB Services <sup>2</sup>
Buy	Buy	49%	40%
Neutral	Hold/Neutrai	42%	35%
Sell	Sell	8%	21%
UBS Short-Term Rating	Rating Category	Coverage <sup>3</sup>	IB Services⁴
Buy	Buy	less than 1%	14%
Sell	Sell	less than 1%	0%

<sup>1:</sup>Percentage of companies under coverage globally within the 12-month rating category.

Source: UBS. Rating allocations are as of 31 December 2010.

## UBS Investment Research: Global Equity Rating Definitions

UBS 12-Month Rating	Definition
Buy	FSR is > 6% above the MRA.
Neutral	FSR is between -6% and 6% of the MRA.
Sell	FSR is > 6% below the MRA.
UBS Short-Term Rating	Definition
Buy	Buy: Stock price expected to rise within three months from the time the rating was assigned because of a specific catalyst or event.
Sell	Sell: Stock price expected to fall within three months from the time the rating was assigned because of a specific catalyst or event.

<sup>2:</sup>Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided within the past 12 months.

<sup>3:</sup>Percentage of companies under coverage globally within the Short-Term rating category.

<sup>4:</sup>Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided within the past 12 months.

#### **KEY DEFINITIONS**

Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend yield over the next 12 months

**Market Return Assumption (MRA)** is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk premium).

**Under Review (UR)** Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or rating are subject to possible change in the near term, usually in response to an event that may affect the investment case or valuation. **Short-Term Ratings** reflect the expected near-term (up to three months) performance of the stock and do not reflect any change in the fundamental view or investment case.

Equity Price Targets have an investment horizon of 12 months.

#### **EXCEPTIONS AND SPECIAL CASES**

**UK and European Investment Fund ratings and definitions are:** Buy: Positive on factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure, management, performance record, discount; Sell: Negative on factors such as structure, management, performance record, discount.

Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant research piece.

Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not registered/qualified as research analysts with the NASD and NYSE and therefore are not subject to the restrictions contained in the NASD and NYSE rules on communications with a subject company, public appearances, and trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate contributing to this report, if any, follows.

UBS Securities LLC: Jim von Riesemann; Julien Dumoulin-Smith; David Eads.

#### Company Disclosures

Company Name	Reuters	12-mo rating	Short-term rating	Price	Price date
PG&E Corporation <sup>2, 4, 5, 6, 16</sup>	PCG.N	Neutral	N/A	US\$47.00	20 Jan 2011


Source: UBS. All prices as of local market close.

Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock pricing date

- UBS AG, its affiliates or subsidiaries has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
- Within the past 12 months, UBS AG, its affiliates or subsidiaries has received compensation for investment banking services from this company/entity.
- 5. UBS AG, its affiliates or subsidiaries expect to receive or intend to seek compensation for investment banking services from this company/entity within the next three months.
- 6. This company/entity is, or within the past 12 months has been, a client of UBS Securities LLC, and investment banking services are being, or have been, provided.
- 16. UBS Securities LLC makes a market in the securities and/or ADRs of this company.

Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report.

## PG&E Corporation (US\$)



Source: UBS; as of 20 Jan 2011

#### Global Disclaimer

This report has been prepared by UBS Securities LLC, an affiliate of UBS AG, UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS. In certain countries, UBS AG is

This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy or recommendation contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. It is published solely for information purposes, it does not constitute an advertisement and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments in any jurisdiction. No representation or warranty, either express or implied, is provided in relation to the accuracy, completeness or reliability of the information contained herein, except with respect to information concerning UBS AG, its subsidiaries and affiliates, nor is it intended to be a complete statement or summary of the securities, markets or developments referred to in the report. UBS does not undertake that investors will obtain profits, nor will it share with investors any investment profits nor accept any liability for any investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by recipients as a substitute for the exercise of their own judgement. Past performance is not necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this necessarily a guide to future performance. The value of any investment or income may go down as well as up and you may not get back the full amount invested. Any opinions expressed in this report are subject to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of UBS as a result of using different assumptions and criteria. Research will initiate, update and cease coverage solely at the discretion of UBS Investment Bank Research Management. The analysis contained herein is based on numerous assumptions. Different assumptions could result in materially different results. The analyst(s) responsible for the preparation of this report may interact with trading desk personnel, sales personnel and other constituencies for the purpose of gathering, synthesizing and interpreting market information. UBS is under no obligation to update or keep current the information contained herein. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS, into other areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this report is determined exclusively by research management and senior management (not including investment banking). Analyst compensation is not based on investment banking revenues, however, compensation may relate to the revenues of UBS Investment Bank as a whole, of which investment banking, sales and trading are a part.

The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates and other market conditions. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report. For investment advice, trade execution or other enquiries, clients should contact their local sales representative. Neither UBS nor any of uBS' or any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC and/or UBS Capital Markets LP) acts as a market maker or liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this research report. UBS and its affiliates and employees may have long or short positions, trade as principal and buy and sell in instruments or derivatives identified herein.

Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results.

can or could have been effected at those prices and any prices do not necessarily reflect UBS's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by UBS or any other source, may yield substantially different results.

United Kingdom and the rest of Europe: Except as otherwise specified herein, this material is communicated by UBS Limited, a subsidiary of UBS AG, to persons who are eligible counterparties or professional clients and is only available to such persons. The information contained herein does not apply to, and should not be relied upon by, retail clients. UBS Limited and understand the presence of the properties of the properties of the properties and these are indicated on the research where applicable. France: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities France SA. Is segulated by the Autorité des Marchés Financiers (AMF). Where an analyst of UBS Securities France SA. As contributed to this report is also deemed to have been prepared by UBS Securities France SA. As Commany: Prepared by UBS Limited and distributed by UBS Limited and UBS Deutschland AG. UBS Deutschland AG is regulated by the Bundesanstalt fur Finanzidensteistungsaufschild (BaFin). Spain: Prepared by UBS Limited and distributed by UBS Limited and UBS Securities España SV, SA. UBS Securities España SV, SA is regulated by the Commission Nacional levents of the Marchés (Santian) of the Securities Securities Securities France SA. As Securities Securities Securities France Securities Securities France Securities Securities France Securities Fran only and is not intriduct distinction in the Clinica Ada Limitation. Note: Not

The disclosures contained in research reports produced by UBS Limited shall be governed by and construed in accordance with English law

UBS specifically prohibits the redistribution of this material in whole or in part without the written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. Images may depict objects or elements which are protected by third party copyright, trademarks and other intellectual property rights. © UBS 2011. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights rese

b II а